Core Viewpoint - The National Healthcare Security Administration (NHSA) is seeking public opinion on the draft of the "Reference Drug Communication Method (Trial)" to enhance the scientific, fair, and standardized selection of reference drugs during the adjustment of the medical insurance drug list [1] Group 1: Policy Changes - The NHSA has introduced the practice of selecting reference drugs during the adjustment of the medical insurance drug list, which serves as an important anchor for calculating drug reimbursement standards [1] - A separate communication phase for reference drugs will be established to allow experts to propose suggestions before the adjustment process begins, thereby improving the selection process [1] Group 2: Support for Innovative Drugs - The reference drug communication work will initially focus on Class 1 new drugs, which include newly registered Class 1 chemical drugs, Class 1 therapeutic biological products, and Class 1 traditional Chinese medicines [1] - Class 1 new drugs that have not yet been approved for market but have had their applications accepted and passed technical review by the National Medical Products Administration can also apply in advance [1]

Core Insights - The company faced revenue pressure but significantly improved profitability, with a 2024 revenue of 4.001 billion yuan (down 2.98% year-on-year) and a net profit of 397 million yuan (down 29.46% year-on-year) [1] - The company reported a gross margin of 57.49% for 2024, an increase of 4.61 percentage points, attributed to a higher proportion of high-margin formulations and optimized raw material costs [1] Revenue Breakdown - In 2024, the formulation sales revenue was 2.415 billion yuan (up 6.02% year-on-year), with significant growth in anesthetic muscle relaxants (up 55%) and respiratory products (up 31%), while generic drug formulation revenue decreased by 19% [2] - Raw material and intermediate revenue fell to 1.547 billion yuan (down 13.4% year-on-year), primarily due to intensified competition and price declines in the non-standard market [2] Growth Potential - The company has a strong pipeline with four new generic drug approvals in 2024, including the first domestic generic version of estradiol valerate tablets [3] - The company is expanding internationally, with raw materials like medroxyprogesterone acetate receiving WHO PQ certification and prednisone receiving PMDA certification in Japan [3] - Earnings per share forecasts for 2025-2027 have been adjusted to 0.69, 0.80, and 0.97 yuan, respectively, with a target price of 11.04 yuan based on a 16x P/E ratio for 2025 [3]